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The degree of progressive chronic histological damage is
associated with long-term renal allograft survival. In order to
identify promising molecular targets for timely intervention,
we examined renal allograft protocol and indication biopsies
from 120 low-risk pediatric and adolescent recipients by
whole-genome microarray expression profiling. In data-
driven analysis, we found a highly regulated pattern of
adaptive and innate immune gene expression that correlated
with established or ongoing histological chronic injury, and
also with development of future chronic histological damage,
even in histologically pristine kidneys. Hence, histologically
unrecognized immunological injury at a molecular level
sets the stage for the development of chronic tissue injury,
while the same molecular response is accentuated during
established and worsening chronic allograft damage.
Irrespective of the hypothesized immune or nonimmune
trigger for chronic allograft injury, a highly orchestrated
regulation of innate and adaptive immune responses was
found in the graft at the molecular level. This occurred
months before histologic lesions appear, and quantitatively
below the diagnostic threshold of classic T-cell or antibody-
mediated rejection. Thus, measurement of specific immune
gene expression in protocol biopsies may be warranted to
predict the development of subsequent chronic injury in
histologically quiescent grafts and as a means to titrate
immunosuppressive therapy.
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published online 31 August 2011
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After renal transplantation, progressive chronic histological
damage is observed in protocol biopsies performed at
predefined time points after transplantation. Cumulative
histological damage is associated with progressive renal graft
dysfunction, reflected by a gradual rise in serum creatinine
and/or development of proteinuria, and ultimately leads to
complete loss of graft function.1–4 This histological damage
has several phenotypes and its etiology is multifactorial.
Both alloimmune (cellular rejection and antibody-mediated
rejection) and non-alloimmune (for example, recurrent or
de novo glomerular disease, calcineurin inhibitor nephro-
toxicity) phenomena are recognized as major contributors
of progressive scarring of the renal allografts, against the
background of changing demographics of kidney transplant
donors and recipients and the acceptance of lower-quality
kidneys for transplantation.5,6
Early detection of chronic tubulointerstitial damage,
especially with concomitant inflammation, has been asso-
ciated with later allograft survival.1,7–9 Early development of
subclinical interstitial fibrosis and tubular atrophy could
therefore be used as predictive marker for long-term graft
outcome.10 However, it has to be emphasized that the real
cause of renal allograft loss is most often a specific disease
process, and tubulointerstitial damage is often the conse-
quence of these specific disease processes rather than the
cause.4,11 Several disease processes can occur concomitantly,
and interstitial fibrosis and tubular atrophy represent the
cumulative burden of renal allograft injury, irrespective of
its etiology.
In human kidney transplantation, using gene expression
microarray technology on renal allograft biopsies, the mole-
cular heterogeneity of renal allografts was demonstrated
at the time of transplantation,12 at the time of acute
rejection,13,14 and after chronic histological damage was
established.15–18 In addition, gene expression analysis has
been performed in protocol biopsies to investigate the
molecular disturbances that accompany progressive chronic
histological damage of renal allografts.19–23 In these studies,
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immune phenomena appear to have a significant role in the
progression of chronic histological damage, and it is
suggested that progressive histological damage is immune
mediated. However, in these previous studies, there was
either no information on the histological inflammatory
burden in the early protocol biopsies that were used to
predict progressive chronic damage,19,20 there were signifi-
cant differences in chronic tubulointerstitial damage and in
graft function at the early protocol biopsy time point,23 or
there were differences in both total inflammatory burden and
chronic histological damage at the early protocol biopsy time
point.22 From these studies, it is unclear whether the immune
gene signatures represent merely established injury, rather
than future and ongoing injury. A study of gene expression at
1 month after transplantation showed increased expression of
immune-related genes in the early biopsy of kidneys with
progressive tubulointerstitial damage.21 However, this study
did not exclude kidneys that experienced biopsy-proven
acute rejection as overt cause of chronic histological damage
progression. Interestingly, a recent study has demonstrated
that the gene expression profile of early (6 weeks) protocol
biopsies reflects mainly peritransplant injury such as delayed
graft function, rather than predicting post-transplant histo-
logical evolution.24
Nevertheless, in many instances, inexorable chronic tubulo-
interstitial injury is noted on the 1-year protocol biopsy,2,6,25,26
in the absence of any clinical or subclinical acute rejection,
infection, or vascular detriment and with histologically quiescent
early protocol biopsies. The question of what drives progressive
chronic histological damage of renal allografts, specifically in
the absence of overt post-transplant injury, thus remains
largely unanswered. This carefully designed study of serial
protocol biopsies performed at prescheduled time points,
with simultaneously collated clinical, histological, and tran-
scriptional data sets, was conducted to elucidate the gene
expression dynamics associated with established, ongoing,
and, most importantly, future histological damage in
pediatric and adolescent patients who received good-quality
kidneys, without the confounding interference of delayed
graft function, graft rejection, or infection. Better insight in
the early pathogenesis of chronic renal allograft damage, in
the absence of clinically overt causes, could bring forward
new targets for timely intervention and prevention of chronic
scarring. In addition, prediction of future damage by early
gene expression assessment could provide clinical guidance
and may ultimately lead to individualized treatment of renal
allograft recipients.
RESULTS
Immune cell activation gene expression in chronic allograft
injury (Project 1)
In Project 1, a case–control analysis was conducted on 48
protocol biopsies with varying degrees of chronic allograft
injury (graded by the Chronic Allograft Damage Index
(CADI) score,1 which was used as surrogate end point for
graft survival), obtained from 48 different patients, and split
equally into a discovery set (protocol biopsies at various time
points) and a validation set (protocol biopsies at 24 months
after transplantation). Mean recipient age and donor age were
10.9±6.1 years and 33.6±11.0 years, respectively, and 35/48
(73.9%) of the kidneys were obtained from living donors
(Table 1 and Figure 1). The distribution of the individual
components of the CADI scores in the different biopsy groups
is represented in Supplementary Figure S1 online.
In the discovery set, 864 probe sets were significantly
differently expressed between biopsies with high CADI score
and biopsies with low CADI score (Table 2); 397 of these
were significantly upregulated in the high CADI score group
(340 unique genes; qo0.05). In biological function assess-
ment of these 397 genes using Ingenuity Pathway Analysis
(IPA), a highly significant enrichment of cell-specific immune
response genes was observed (P¼ 7.99 1043), with signi-
ficant enrichment of T-lymphocyte (P¼ 1.06 1023) and
B-lymphocyte (P¼ 1.01 1011) proliferation transcripts,
transcripts involved in natural killer (NK) cell activation
(P¼ 4.75 107), mast cell activation (P¼ 4.95 108),
dendritic cell migration (P¼ 6.65 106), and granulocyte
migration (P¼ 5.64 1011; Table 2 and Figure 2a).
In the validation set, again comparing biopsies with high
versus low CADI score, we found differential expression of
804 probe sets (703 probe sets upregulated; qo0.05).
Pathway analysis confirmed a highly significant enrichment
of immune response genes and enrichment of the different
immune cell types (Table 2 and Figure 2b).
Although enrichment analysis of the 397 and 703 probe
set lists showed remarkable overrepresentation of immunity-
related functions, scattered nonimmune biological functions
were also significantly enriched, without clear immediate
relevance for organ transplantation (Supplementary Tables
S1 and S2 online).
Schwartz glomerular filtration rate (GFR; ml/min per
1.73m2) was not associated with these gene set scores, neither
in the discovery set nor in the validation set (data not shown).
Gene expression dynamics and CADI score progression over
time (Project 2)
Project 2 consisted of a longitudinal analysis of 72 serial
protocol biopsies from 24 patients, each of whom underwent
biopsies at implantation, at 6 and 24 months. None of these
patients experienced Banff-grade acute T-cell-mediated
rejection within the first 2 years after transplantation. To
mitigate the confounding influence of donor quality and
extended ischemia time on gene expression changes,
previously shown by our group,12 the sample set was
carefully selected such that kidney graft quality was excellent
at implantation, with minimal chronic damage and a mean
Remuzzi score27 of only 0.63±0.81 (median 0, range 0–2).
Despite the pristine tissue quality at engraftment, as also
previously shown by our group,28 the effect of increasing
post-transplant time, even in the absence of interval acute
rejection, results in a significant increase in chronic
histological damage in all histological compartments. At 24
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months after transplantation, 50% of the group (12 patients;
36 biopsies) had significantly greater histological progression,
scored by the incremental CADI score, and for analysis
purposes, have been labeled the progressor group, and gene
expression data in this group have been compared with the
remainder of the patients, who, for purposes of analysis, have
been called the nonprogressor group. At 6 months, the
progressors had higher mean CADI scores than the nonpro-
gressors (3.2±1.8 vs. 0.75±0.75; P¼ 0.0003), and similar
trends were seen for mean CADI scores for the 24-month
biopsies (7.3±1.6 in progressors, in contrast to 1.8±1.4 in
nonprogressors; Po0.0001). No other Banff qualifiers were
significantly different at any time point (Table 1 and
Supplementary Figure S2 online).
In an unpaired timeline analysis (signed area test) of the
serial biopsies (0, 6, and 24 months after transplantation),
we found significantly different evolution in the expression
of 601 probe sets that mirrored the histological evolution of
chronic injury over time (qo0.05). Using IPA, the histo-
logical evolution of chronic histological injury in the graft,
even in the absence of any histological evidence of acute
rejection, had a strong signal for an activation state of
different immune cells (P¼ 1.35 1091) involved in T- and
B-cell proliferation (P¼ 1.03 1031 and 1.89 1021, respec-
tively), NK cell (P¼ 1.63 1012), mast cell (P¼ 4.49 1011),
dendritic cell activation (P¼ 3.57 1021), and granulocyte
migration (P¼ 2.19 1028; Table 2 and Figure 3). Although
enrichment analysis of the 601 probe set list showed remark-
able overrepresentation of immunity-related functions,
scattered nonimmune biological functions were signifi-
cantly enriched, without clear immediate relevance for organ
transplantation (Supplementary Table S3 online).
There was no correlation between gene set scores at
implantation and post-transplantation graft function. Gene
set scores obtained at 6 months correlated significantly
but positively with Schwartz GFR (ml/min per 1.73m2) at
6 months (Po0.05 for T-cell proliferation, B-cell prolifera-
tion, NK cell activation, granulocyte migration, and dendritic
cell migration). Gene set scores at 6 months were, however,
not associated with later graft function. There was no corre-
lation between gene set scores obtained at 24 months and
graft function at this time point (data not shown).
Association of 6 months gene expression with CADI score
at 24 months (Project 3)
We next interrogated the gene expression changes in the
6-month biopsies as a means to predict the evolution of
histological injury in the same graft, when sampled by biopsy
18 months later. We compared gene expression of 6-month
biopsies of the progressor group with gene expression of
6-month biopsies of the nonprogressor group and performed
an associative significance analysis of microarray (SAM)
analysis. A total of 92 probe sets were significantly over-
expressed in the 6-month biopsies of the progressor group
(qo0.05) and again, by IPA, there was a significant enrich-
ment of similar immune genes (P¼ 0.0001), having a role in
T- and B-cell proliferation (P¼ 0.003 and 0.003, respec-
tively), NK cell activation (P¼ 0.04), and migration of
Project 1
Gene expression and CADI score
Projects 2 and 3
Gene expression dynamics and CADI score
over time after transplantation
Discovery set
(n = 24 post-TX protocol biopsies)
Low CADI score
(n = 12 biopsies)
Low CADI score
(n = 12 biopsies)
High CADI score
(n = 12 biopsies)
n = 72 post-TX biopsies from 72 patients
Low CADI score
(n = 24)*
High CADI score
(n = 24)*
Rejection
(n = 24)**
Project 4
Immune gene set scores as a quantitative marker for inflammation
24 Months – low CADI
score (n = 12 biopsies)
‘Nonprogressors’ $
6 Months – low CADI score
(n = 24 biopsies)
0 Months
(n = 24 protocol biopsies)
24 Months – high CADI
score (n = 12 biopsies)
‘Progressors’ #
Validation set
(n = 24 protocol biopsies at 24 mo)
High CADI score
(n = 12 biopsies)
Figure 1 |Classification of the 120 renal allograft biopsy samples included in the current study. *Compilation of discovery sets
and validation sets from Project 1. **Patients different from those in Projects 1–3. CADI, Chronic Allograft Damage Index; mo, months;
TX, transplantation. $The same data set as the low CADI group of the validation set of Project 1. #The same data set as the high CADI group
of the validation set of Project 1.
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dendritic cells (P¼ 0.001; Table 2 and Figure 4a). Although
enrichment analysis of the 92 probe set list again showed
overrepresentation of immunity-related functions, scattered
nonimmune biological functions were significantly enriched,
without clear immediate relevance for organ transplantation
(Supplementary Table S4 online).
There was a significant association between these immune
gene set scores in these 6-month biopsies and future
histological damage progression (Figure 4a). Classification
models can be built with area under the receiver operating
characteristic curves greater than 0.82, for predicting the
downstream evolution of chronic histological allograft injury
by these gene set scores (Figure 4b).
Immune gene set scores as quantitative parameters for
inflammation (Project 4)
Given the strong immune cell activation signal associated
with the detection and evolution of chronic histological
injury alone, we next included gene expression analysis for
indication biopsies with histological evidence of Banff-graded
acute rejection to compare and contrast the extent of immune
activation signals between acute rejection and chronic graft
injury without acute rejection. For this purpose, we conducted
Project 4, which consisted of 72 unique biopsies; 48 biopsies
from patients with chronic graft injury (from Project 1) and
24 for-cause biopsies with Banff-grade acute T-cell-mediated
rejection. As expected, histological parameters were signi-
ficantly different between the 48 rejection-free protocol
biopsies and the 24 biopsies with acute rejection (Table 1
and Supplementary Figure S3 online).
The immune gene set scores for chronic histological injury
signals, developed in the earlier Projects, demonstrate that
there is a highly regulated environment of subclinical inflam-
mation in the graft that associates with the progression of this
injury. We wanted to elucidate whether immune gene set
scores are also increased in clinically relevant inflammation
(Banff-graded T-cell-mediated acute rejection). We noted
significantly higher immune gene set scores in acute rejection
biopsies compared to biopsies with low CADI score. The
immune gene set scores in acute rejection biopsies were
comparable with or even higher than the gene set scores
observed in biopsies with a high CADI score (Figure 5a).
The correlation between the different immune gene set scores
and the different histological lesions is shown in Figure 5b.
The correlation was best for total i-score, which represents
the total inflammatory burden in the graft. These data
suggest that the extent of graft inflammation, either clinical
or subclinical, follows the same paradigm of inflammatory
cell-specific signals, and the persistence of this injury,
undetected by histological evaluations, programs the host
tissue to inexorable cellular injury and fibrosis. It is thus clear
that the gene expression signature of clinical acute cellular
rejection with tubulitis is very similar to the signature of
progressive chronic tissue damage in the absence of tubulitis,
and the extent of inflammatory burden may be a threshold
effect that could be a factor that determines the developmentT
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of tubulitis and clinical acute rejection. Throughout the study
(N¼ 120 biopsies), there was no association between steroid
use and intragraft immune gene expression.
DISCUSSION
Slowly progressive chronic histological damage associates
with long-term renal allograft survival. This injury is
accelerated in grafts that undergo acute rejection; however,
in the absence of the injury of interval allograft rejection, the
driving molecular forces behind progressive histological
damage are not known.
This paper reports on an in-depth study on the correlation
between the subclinical histological evolution of renal
allografts and whole-genome gene expression in renal
allograft recipients with low immunological risk. By access
to serially collected protocol biopsy samples, with centralized,
blinded semiquantitative histological scores, a highly selected
set of biopsies was used for interrogation of the molecular
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Figure 2 |Gene expression and CADI score (Project 1). After significance analysis of microarrays, comparing gene expression of biopsies
with high versus low CADI score, the probe set lists were analyzed using the Ingenuity Pathway Analysis program (Ingenuity Systems)
and demonstrated highly significant enrichment of immune genes. The immune gene set scores represented in the graphs were calculated
as the geometric mean of fold changes (unlogged values) across all probe sets (not only the significant probe sets) within the Ingenuity
Pathways Knowledge Base (IPKB) lists for the different immune cell functions (Supplementary Table S5 online). (a) Comparison of the
immune gene set scores between biopsies with high versus low CADI scores in a discovery set (n¼ 24) and (b) in a validation set (n¼ 24).
P-values represented in the graphs were calculated using Mann–Whitney tests. The error bars represent mean±standard error of the mean.
CADI, Chronic Allograft Damage Index; NK, natural killer; TX, transplantation.
Kidney International (2011) 80, 1364–1376 1369
M Naesens et al.: Molecular profile of progressive allograft injury o r ig ina l a r t i c l e
processes that associate with chronic histological injury, in
the absence of any graft dysfunction. We used microarray
technology applied on kidney biopsy tissue samples obtained
at preset time points in the first 2 years after transplantation.
The very strict selection of only pristine kidneys at time of
transplantation without any donor pathology, the absence of
delayed graft function, the exclusion of patients with allograft
rejection in the main analysis, the exclusion of patients with
de novo or recurrent glomerular disease and donor-specific
antibodies, and in-depth statistical analysis integrating pathology
scores, expression measurements, and gene set scores allowed
us to uncover the molecular mechanisms associated with
established histological injury and to predict histological
damage progression in the early post-transplant period.
Using a cross-validated genomewide transcript analytical
approach, we confirm the highly significant association of
established chronic histological damage with the coordi-
nated regulation of adaptive and innate immune response
genes,16,22,29,30 in the absence of Banff-grade acute T-cell-
mediated or antibody-mediated rejection. Despite the
absence of rejection in these protocol biopsies, the expression
profile of the biopsies with established chronic damage is
remarkably similar to biopsies with acute rejection. The
highly significant correlation between the immune cell-
associated transcript scores and the Banff interstitial
inflammation and tubulitis scores, inflammation in atrophic
areas and especially the recently proposed31 total i-score
in our study, suggest that it is this cellular infiltration
and inflammation that largely explains the gene expres-
sion profile variability. However, the finding that the
correlation between immune cell infiltrates (inflammation
in atrophic areas and total i-score) and immune cell
transcript scores remains highly significant in the absence
of inflammation in viable tissue (Banff i- and t-scores equal
to zero; data not shown) demonstrates that microarray
analysis performed on whole tissue cores is able to detect
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Figure 3 |Gene expression dynamics and CADI score over time after transplantation (Project 2). Enrichment analysis of the probe set
list that was generated from unpaired time course analysis (signed area test on 72 serial protocol biopsies at 0, 6, and 24 months after
transplantation) comparing progressors (N¼ 12 patients) with nonprogressors (N¼ 12 patients) showed highly significant enrichment of
immune genes involved in both innate and adaptive immunity. The immune gene set scores represented in the graphs were calculated
as the geometric mean of fold changes (unlogged values) across all probe sets (not only the significant probe sets) within the Ingenuity
Pathways Knowledge Base lists for the different immune cell functions (Supplementary Table S5 online). P-values represented in the graphs
were calculated using repeated measures analysis of variance. The error bars represent mean±standard error of the mean. The significant
P-values of the enrichment analysis from the comparison between progressors and non-progressors are given in Table 2 (Project 2).
CADI, Chronic Allograft Damage Index; NK, natural killer; NS, nonsignificant.
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Figure 4 |Association of 6 months gene expression with CADI score at 24 months (Project 3). (a) After significance analysis of
microarrays, comparing gene expression of 6-month biopsies of progressors versus nonprogressors, the probe set list was analyzed using
the Ingenuity Pathway Analysis program (Ingenuity Systems) and demonstrated significant enrichment of immune genes. The immune
gene set scores represented in the graphs were calculated as the geometric mean of fold changes (unlogged values) across all probe
sets (not only the significant probe sets) within the Ingenuity Pathways Knowledge Base lists for the different immune cell functions
(Supplementary Table S5 online). P-values represented in the graphs were calculated using Mann–Whitney tests. The error bars represent
mean±standard error of the mean. (b) Receiver operating characteristic-curve analysis demonstrates good accuracy of the 6-month
immune gene set scores for prediction of subsequent damage. AUC, area under the curve; CADI, Chronic Allograft Damage Index;
NK, natural killer.
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Figure 5 | Immune gene set scores as quantitative marker for inflammation (Project 4). (a) There was a gradual association between
the CADI score/T-cell-mediated rejection and the different immune gene set scores, as calculated from the Ingenuity Pathways Knowledge
Base. Therefore, these immune gene set scores not only represent a good marker for ongoing and future chronic histological damage, but
also offer a quantifiable measure for other types of inflammation in the graft. P-values represented in the graphs were calculated using
Kruskall–Wallis tests. The error bars represent mean±standard error of the mean. (b) Spearman correlation analysis between histological features
and gene set scores in the 48 rejection-free biopsies (left panel) and the 72 biopsies (48 rejection-free biopsiesþ 24 biopsies with T-cell-mediated
rejection) included in Project 4. The numbers given in the boxes represent correlation coefficients; the filled colors correspond to the statistical
significance of the correlation. Even in the absence of rejection (left panel), the correlation between the scores of histological inflammation
and inflammatory gene set scores was high (especially for inflammation in atrophic areas and the total i-score), which demonstrates that the gene
sets capture subtle inflammation. When rejection biopsies were included in the correlation analysis (right panel), interstitial inflammation
and tubulitis correlated highly significantly with the gene set scores. The gene set scores therefore represent a global assessment of the
inflammatory burden (without information of the exact anatomical localization of the cells that express the inflammatory genes) and a quantitative
marker for ongoing inflammation, from moderate subclinical inflammation associated with chronic histological damage to marked inflammation
of Banff-grade acute T-cell-mediated rejection. CADI, Chronic Allograft Damage Index; IF/TA, interstitial fibrosis/tubular atrophy; NK, natural killer;
NS, nonsignificant.
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even subtle inflammation, below the diagnostic threshold
of histological diagnosis as defined by the current Banff
classification. This is consistent with previous studies also
showing the good correlation between the total i-score
and T-cell-associated transcripts, g-interferon-associated
transcripts, B-cell transcripts, and mast cell increase,11,17,32
and highlights the fact that the gene expression of tissue
biopsies represents a global assessment of the inflammatory
burden within a biopsy.
Most importantly, our study shows that the upregulation
and overrepresentation of immunity genes is not solely a
feature of biopsies with established chronic damage. Instead,
upregulation of adaptive (T- and B-cell signatures) and
innate immune cell transcripts (dendritic cell and NK cell
transcripts) is already present in biopsies of kidneys several
months before chronic histological damage occurs. This
illustrates that the immune gene set scores used in the current
study represent a quantifiable parameter of total inflamma-
tory burden in a biopsy with a very wide dynamic range:
from subtle inflammatory activity before development of
histological lesions, over moderate subclinical inflammatory
gene expression associated with ongoing and established
chronic histological damage, to marked overexpression of
inflammatory genes in biopsies with Banff-grade acute T-cell-
mediated rejection. The association of later histological
damage with molecular disturbances of immune genes in
early protocol biopsies was also seen in adult renal
transplantation programs.20–23 Although these previous
studies adequately illustrate the importance of immune-
related gene expression tracking together with progression of
chronic histological damage, our study is the first to illustrate
the association of total inflammatory burden in pristine early
protocol biopsies with progression of chronic tubulointer-
stitial damage, below the current histological diagnostic
thresholds and in the absence of acute rejection episodes. The
studies in adult renal transplant recipients either included
patients with interval acute rejection21 or predictor biopsies
with significant inflammation or chronic damage,22,23 which
could have influenced the results considerably as the gene
expression signatures in these studies are essentially derived
from comparisons between biopsies with and without
histologically evident damage.
The coregulation of both innate and adaptive immune
genes illustrates the complex interplay between innate and
adaptive immune responses in a transplantation setting.33
These subtle inflammatory changes in renal allografts are
likely very important, as an association between T-lympho-
cyte-mediated inflammation in scarred areas and graft
outcome was demonstrated previously,9 which suggests
continuing effects of these inflammatory infiltrates on the
scarring process. Importantly, however, especially in the light
of possible therapeutic interventions, the current study
supports the growing theory that other immune cell types
such as B cells,13,34,35 NK cells,36–38 dendritic cells,39–41 mast
cells,17,42,43 and granulocytes44,45 are involved in chronic renal
allograft damage and may be driving the immunological
processes after transplantation, potentially by their implica-
tion in antigen presentation, in the secretion of inflammatory
cytokines, and in the regulation of T cells.
The preemptive finding of both cell-specific enrichment
for a panel of immune cells and immune activation
signatures in the graft suggests that both infiltration and
activation of the infiltrating cells are critical triggers for the
development and progression of alloreactive chronic injury.
Nevertheless, in this human study, it is not possible to
distinguish the relative impact of alloreactivity from
nonspecific injury mechanisms in the graft. We emphasize
that the CADI score used in our study does not help to
differentiate between the different pathogenic processes that
have a role in the progression of the histological damage, as
the lesions included in the CADI score are all nonspecific.
After the description of these gene signatures in nonspecific
chronic histological damage progression and in acute cellular
rejection, as was done in the current study, it will be
necessary to study the potential usefulness of these immune
gene signatures in other inflammatory disease processes such
as de novo or recurrent glomerular disease, polyomavirus
nephropathy, antibody-mediated rejection and pyelonephri-
tis, and in noninflammatory renal pathology such as acute
tubular necrosis or postrenal obstruction. However, from the
current study, it could be hypothesized that much of the
progression of chronic damage is inflammation mediated,
irrespective of the specific disease process. The immune gene
signatures could potentially be used as nonspecific but very
sensitive markers for future and ongoing subclinical injury.
Whether this is sufficient to yield a useful clinical biomarker
to guide therapeutic decisions is another question that can
only be answered through further refinement and simplifica-
tion of the gene expression biomarker, and extensive
validation studies.
Although it is tantalizing to hypothesize that increased
immunosuppression in the patients with high immune gene
set scores could prevent or even reverse progressive chronic
histological damage, further studies in animals and con-
trolled immunosuppression trials in humans are suggested
and necessary to elucidate whether the spectrum of
histological damage responds to increased or, more likely,
targeted immunosuppression. This study was performed in
pediatric and young adult renal allograft recipients with low
immunological risk. Moreover, these patients were treated
with the combination of tacrolimus and mycophenolate
mofetil, the most common immunosuppressive drug combi-
nation in current clinical practice. Therefore, additional
validation of the intragraft injury responses should be done
in patients with higher immunological risk, in patients
treated with other immunosuppressive drug regimens and in
adult recipients, as the mechanisms contributing to chronic
histological damage could differ between populations, both
in terms of risk for subclinical alloimmune problems as in
terms of nonimmune injury such as relative renal hypo-
perfusion in adult-sized kidneys transplanted into infant
recipients.28
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Clinical follow-up time of the current study is too short to
make any conclusion about the impact of early molecular
disturbance or histological damage progression on long-term
outcome and hard clinical end points. Much larger studies
with longer clinical follow-up time and a cross-sectional trial
design will be needed to address this issue. The Schwartz GFR
(ml/min per 1.73m2) did not correlate with the molecular
disturbances, apart from a positive correlation of higher
Schwartz GFR with increased expression of immune genes at
6 months after transplantation. Although this finding was not
consistent throughout the study projects, this significant
correlation could be explained by the relatively high Schwartz
GFR in the youngest patients, who not only have the best
Schwartz GFR but also most histological damage, likely
through chronic ischemia secondary to size-discrepant
kidney transplantation.28
The careful selection of patients for inclusion in the
current study was necessary to avoid interference of clinical
factors contributing to chronic allograft damage, as it was
confirmed recently that gene expression in the earliest phase
post-transplantation (at 6 weeks) reflects mainly peritrans-
plant injury, without information of the fate of the kidney
transplant in the long term.24 Our study supports the idea
that a protocol biopsy performed at a later stage (6 months),
when peritransplant injury has largely faded away, provides a
better view on the future of a kidney allograft. However, even
in this study of completely pristine kidneys without delayed
graft function and with exclusion of overt post-transplanta-
tion complications, all kidney allografts inevitably went
through some injury during harvest and reperfusion. It can
therefore not be completely ruled out that the observed
changes are still a consequence of this early injury, and the
molecular disturbances observed could still reflect the healing
of tissue instead of new injury processes. In this light, it
should be taken into account that in clinical practice different
injury processes can occur simultaneously and patients do
not always have a clear and straightforward histological
evolution. Apart from peritransplant injury, transplanted
kidneys also experience rejection episodes, recurrence of the
original disease, viral or bacterial infections, episodes of
dehydration or ischemia, cardiovascular events, and other
factors that affect renal allograft histology, renal graft
function, and graft survival. It is therefore clear that a biopsy
performed at 6 months after transplantation cannot foresee
the future of every graft. Nevertheless, this study provides a
road map of the molecular basis of the tissue injury that may
be programmed to occur.
CONCLUSION
In conclusion, the current study demonstrates that progres-
sive chronic histological damage after kidney transplantation
is associated with regulation of both innate and adaptive
immune responses that cannot be currently evaluated by
histology. There is involvement of a broad spectrum of
immune mediators such as T cells, B cells, NK cells, mast
cells, granulocytes, and dendritic cells. This study therefore
underscores the complexity of the immunological processes
in human kidney transplantation, and corroborates the idea
that inflammation that is quantitatively below the diagnostic
threshold of acute T-cell-mediated rejection is involved in
early subclinical stages of progressive renal allograft damage.
Timely intervention aimed at influencing these early immune
responses or turn these inflammatory signals into a more
adaptive state could well be the clue to slow or abort the
progression of chronic renal graft scarring and improve long-
term graft survival.
MATERIALS AND METHODS
Patients and biopsies
The study comprised 120 renal allograft biopsies from 67 pediatric
and adolescent kidney allograft recipients (1–21 years of age). All
biopsies included in this study were selected on the basis of tissue
availability, conduct of blinded and centralized histological evalua-
tion, and adequate RNA quality (see below). All patients received an
immunosuppressive regimen consisting of a combination of tacro-
limus (Prograf, Astellas Pharma US, Deerfield, IL), mycophenolate
mofetil (Cellcept, Hoffman-La Roche, Nutley, NJ), and daclizumab
(Zenapax, Hoffman-La Roche). Some patients received a steroid-
avoidance regimen, whereas others received a steroid-based
immunosuppressive regimen, as described previously.46 Excellent
quality deceased donor kidneys were used following rigid donor
selection criteria and living donor kidneys were obtained from
young adults (mostly parental donors). There was no delayed graft
function in patients included in this study; delayed graft function
in our center was defined as the absence of a 450% decline in
the recipient serum creatinine in the first 72 h and/or requirement
for dialysis in the first week post-transplant. All patients or their
parents gave written informed consent, and the study was approved
by the institutional review board of Stanford University. For
inclusion in the study, patients needed to have a clear histological
evolution, that is, either absence of progression of chronic
histological damage or clear progression of histological damage.
Patients who had unexplained regression of chronic damage (likely
due to sampling error problems) and patients with de novo or
recurrent glomerular disease or donor-specific antibodies were
excluded from the study.
The classification of the biopsies is given in Figure 1 and in
Table 1. The study comprised four projects: (1) case–control analysis
of the differences in gene expression between biopsies with high
versus low CADI score; (2) repeated measures analysis of the
dynamics of gene expression over time after transplantation,
in kidneys with versus without progression of the CADI score;
(3) prediction of future histological damage in six months biopsy
samples from a longitudinal cohort of patients with serial biopsies;
(4) case–control analysis of the gene expression signature of acute
T-cell-mediated rejection in indication biopsies versus rejection-
free protocol biopsies with low or high CADI scores. In Project 1,
48 protocol biopsies with low (N¼ 24) and high (N¼ 24) CADI
scores were included, divided into a discovery and validation set.
In Project 2, 72 protocol biopsies were examined from 24 unique
patients at each of the following time points: at implantation, 6 months,
and 24 months. Patients were categorized into a progressor group
when the histological CADI score reached at least 6 within the first
2 years after transplantation. All other patients were categorized as
nonprogressors. Project 3 comprised the 24 protocol biopsies in
Project 2 obtained at 6 months. In Project 4, gene expression profiles
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of 24 for-cause biopsies showing acute T-cell-mediated rejection
(indication biopsies performed because of graft dysfunction), obtained
in a separate group of patients, were compared with the profiles of
the 48 protocol biopsies from Project 1 (Figure 1 and in Table 1).
The biopsies were classified into the respective groups by manual
selection based on clinical demographics and histological para-
meters to match cases and controls. This grouping was performed
independent of the gene expression results. No biopsies with
antibody-mediated rejection or patients with donor-specific anti-
bodies were included in this study, and patients with BK
nephropathy and specific glomerular disease (recurrent or de novo)
were excluded.
Histological evaluation
All biopsy slides (n¼ 120) were rescored semiquantitatively
according to the revised Banff criteria31 for the severity of acute
histological lesions (interstitial inflammation (i), tubulitis (t),
intimal arteritis (v), glomerulitis (g), inflammation in atrophic
areas) and of chronic histological lesions (tubular atrophy, TA (ci),
interstitial fibrosis, IF (ct), vascular intimal thickening (cv),
arteriolar hyalinosis (ah), increase in mesangial matrix (mm),
transplant glomerulopathy (cg), with the addition of the number of
globally sclerosed glomeruli (gs), the ‘total i-score’,31 and the CADI
score1) (Supplementary Methods online). For implantation biopsies,
we calculated the ‘Remuzzi score’.27
RNA extraction, quality control, amplification, and
hybridization
RNAwas extracted from each kidney allograft biopsy and hybridized
onto Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays
after RNA integrity was ensured and after RNA amplification
(Supplementary Methods online). For processing and normaliza-
tion of the scanned images, dChip 2006 software was used, with
perfect match (PM)/mismatch (MM) difference modeling and
invariant set normalization.47
Study design, data processing, and analysis
Significance analysis of microarrays (SAM) for two-class unpaired
data (Projects 1 and 3) or two-class unpaired time course data
(signed area test; Project 2) was performed to detect expression
differences based on q-values (false discovery rates).48 SAM is an
unbiased statistical technique for finding significant genes in a set
of microarray experiments. The input to SAM is gene expression
measurements from a set of microarray experiments, as well as
a response variable from each experiment. SAM uses repeated
permutations of the data to determine whether the expression of
each gene is significantly related to the response. Significance levels
were set at a q-value of 5%.
After identifying and validating the differentially expressed genes,
these probe sets were analyzed using IPA (Ingenuity Systems,
Redwood City, CA) in order to assess their biological functions and
examine canonical pathways based on the Ingenuity Pathways
Knowledge Base. Gene set scores were calculated as the geometric
mean of fold changes (unlogged values) across all probe sets (not
only the significant probe sets) within the Ingenuity Pathways
Knowledge Base lists for the different immune cell functions
(Supplementary Table S5 online). Gene set scores were compared
between groups with Mann–Whitney test, Kruskall–Wallis test, and
repeated measures analysis of variance, as appropriate. The raw
data sets for the 120 biopsies included are deposited at the Gene
Expression Omnibus under GSE25902.
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